Comprehensive analysis of body composition features in melanoma patients treated with tyrosine kinase inhibitors.
Miriam MengoniAndreas Dominik BraunMattes Simon HinnerichsAnar AghayevThomas TütingAlexey SurovPublished in: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG (2024)
Our study represents the first exploratory study evaluating the suitability of body composition measurements as biomarkers for melanoma patients treated with TKI. Our data suggest a putative use of VATGI as a biomarker predicting patient outcome.